Skip to content
Homepage
Author:
ALX Oncology
Posted Date:
June 30, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology
June 30, 2026
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
ALX Oncology
June 30, 2026
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
ALX Oncology
June 1, 2026
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology
May 8, 2026
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
ALX Oncology
May 7, 2026
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
ALX Oncology
April 30, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology
April 17, 2026
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
ALX Oncology
April 13, 2026
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ALX Oncology
February 27, 2026
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
ALX Oncology
February 19, 2026
1
2
Next
